Who is eligible for clinical trial NCT06335914?

Participants must meet protocol criteria for Advanced Prostate Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06335914 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-09

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer (NCT06335914)

🟢 Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: University Health Network, Toronto

🩺 Plain-English Summary (8th-Grade Level)

This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (10 items).

Location: Princess Margaret Cancer Centre — Toronto, Ontario

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male, age ≥ 18 years
Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
Poor risk patients with mCSPC at study enrollment
De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Under a randomized-controlled trial with unknown allocation of systemic therapy
Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
Unable to provide written consent by patient and their legal representatives
In the opinion of the treating physician:
conditions which would significantly impair the patient's ability to comply with study procedures and follow up
Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
another active malignancy
patient on dialysis
another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Princess Margaret Cancer Centre — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗